Schering-Plough 4Q Revenues: $3.7 billion (+41%)   4Q Loss: $3.3 billion (earnings were $204 million in 4Q06) FY Revenues: $12.7 billion (+20%) FY Loss: $1.5 billion (earnings were $1.1 billion FY06) Comments: Global pharmaceutical sales for the quarter totaled $3.0 billion (+34%). Growth in the quarter was driven by Remicade sales, up 35% to $455 million; Nasonex sales, up 7% to $271 million; Sales of Pegintron, up 15% to $239 million; Temodar sales, up 23% to $234 million; Clarin...